Provectus Biopharmaceuticals Launches Veripure™, an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium)
Provectus Biopharmaceuticals, Inc. (PVCT) Shareholder/Analyst Call Transcript
Provectus Biopharmaceuticals Announces Investor Webinar for 2026 Annual Meeting of Stockholders
Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End
Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus's VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis
Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis
Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee
Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee
Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment
Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Up 16,004.0% in December
Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for Improving Hepatitis B Vaccine Efficacy
Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer
Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer
Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders
Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus's Spinoff Company for Rose Bengal-Based Eye Drugs
Provectus Biopharmaceuticals, Inc. (PVCT) Q4 2024 Earnings Call Transcript
Provectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference Call
Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccines
Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting
Provectus Biopharmaceuticals Announces Acceptance of Pharmaceutical-Grade Rose Bengal Sodium Abstract for Poster Presentation at 2024 Society for Investigative Dermatology (SID) Annual Meeting
Provectus Biopharmaceuticals, Inc. (PVCT) Q1 2024 Earnings Call Transcript
Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call
Provectus Biopharmaceuticals Engages irlabs for Investor Relations Services
Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine Adjuvant
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous Melanoma
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal Melanoma
Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentations at Society for Melanoma Research (SMR) 2023 Congress
Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentations at Society for Melanoma Research (SMR) 2021 Congress
Provectus Biopharmaceuticals Announces Presentation of Full Study Data from Metastatic Neuroendocrine Cancer Phase 1 Trial of PV-10® at European Society for Medical Oncology (ESMO) Congress 2021
Provectus Biopharmaceuticals Announces Acceptance of PV-10® Neuroendocrine Cancer Abstract at European Society for Medical Oncology (ESMO) Congress 2021
Provectus Biopharmaceuticals Announces Publication of In Vitro Data from Research on Oral Delivery of PV-10® at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
State of Tennessee Awards Funding for Public-Private Partnership to Study Animal Cancers and Dermatological Disorders using Provectus' Medical Science Platform
Provectus Biopharmaceuticals Announces Acceptance of PV-10® Immunotherapy Abstracts at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
Provectus Biopharmaceuticals Announces Publication of Australian Compassionate Use Patients Treated with PV-10® Immunotherapy for In-Transit Melanoma Lesions
Provectus Biopharmaceuticals Receives Notice of Allowance for Adult Solid Tumor Cancer Combination Therapy Patent for PV-10® Immunotherapy from United States Patent and Trademark Office
Provectus Biopharmaceuticals Receives Notice of Allowance for Refractory Pediatric Solid Tumor Cancer Monotherapy and Combination Therapy Patent for PV-10® Immunotherapy from United States Patent and Trademark Office
Provectus Biopharmaceuticals Will Hold Its 2016 Third Quarter Business Update Conference Call on Monday, November 14, 2016, at 4 PM Eastern Standard Time
Provectus Biopharmaceuticals Will Hold Its 2016 Second Quarter Business Update Conference Call on Wednesday, August 10, 2016, at 4 PM Eastern Daylight Time
Provectus Biopharmaceuticals Will Hold Its 2016 First Quarter Business Update Conference Call on Tuesday, May 10, 2016, at 4 pm Eastern Daylight Time
Provectus Biopharmaceuticals to Host Its Quarterly Year-End 2015 Financial Business Update Conference Call Wednesday, March 30, 2016 at 4 pm (EDT)
Provectus Biopharmaceuticals to Host Fourth Quarter, Year-End 2015 Conference Call Wednesday, March 16, 2016, at 4 PM EDT
Provectus Biopharmaceuticals Announces Leadership Changes
Provectus Biopharmaceuticals to Host Fourth Quarter, Year-End 2015 Conference Call Thursday, March 10, 2016, at 4 PM EST
Provectus Biopharmaceuticals Will Hold Its 2015 Third Quarter Business Update Conference Call on Thursday, November 5, 2015, at 5 PM Eastern Standard Time
Provectus Biopharmaceuticals Will Hold Its 2015 Second Quarter Business Update Conference Call on Thursday, August 6, 2015, at 4 PM Eastern Daylight Time
Provectus Biopharmaceuticals Will Hold Its Quarterly Business Update Conference Call at 4 PM Eastern, Thursday, May 7, 2015
Provectus Biopharmaceuticals Will Hold Its 2014 Year-End Quarterly Business Update Conference Call at 4 PM Eastern, Thursday, March 12, 2015
Provectus Biopharmaceuticals, Inc. to Hold Quarterly Conference Call on Thursday, November 6, 2014
Provectus Biopharmaceuticals Inc. to Commence Series of Quarterly Conference Calls on Thursday, August 7, 2014